Literature DB >> 26486790

The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS).

Maria Høtoft Michaelsen, Kishor M Wasan, Olena Sivak, Anette Müllertz, Thomas Rades.   

Abstract

A super-saturated self-nanoemulsifying drug delivery system (super-SNEDDS), containing the poorly water-soluble drug halofantrine (Hf) at 150% of equilibrium solubility (S eq), was compared in vitro and in vivo with a conventional SNEDDS (75% of S eq) with respect to bioavailability and digestibility. Further, the effect of digestion on oral absorption of Hf from SNEDDS and super-SNEDDS was assessed by incorporation of the lipase inhibitor tetrahydrolipstatin (orlistat) into the SNEDDS. The SNEDDS contained soybean oil/Maisine 34-I (1:1), Kolliphor RH40, and ethanol at a ratio of 55:35:10, w/w percent. For the dynamic in vitro lipolysis, the precipitation of Hf at 60 min was significantly larger for the super-SNEDDS (66.8 ± 16.4%) than for the SNEDDS (18.5 ± 9.2%). The inhibition of the in vitro digestion by orlistat (1% (w/w)) lowered drug precipitation significantly for both the super-SNEDDS (36.8 ± 1.7%) and the SNEDDS (3.9 ± 0.7%). In the in vivo studies, the super-SNEDDS concept proved valid in a rat model with a significantly larger C max for the super-SNEDDS (964 ± 167 ng/mL) than for the SNEDDS (506 ± 112 ng/mL). The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively). However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively). These findings suggest that the role of lipid digestion for the absorption of drugs from SNEDDS may be less important than previously thought.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26486790      PMCID: PMC4706280          DOI: 10.1208/s12248-015-9832-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  29 in total

1.  Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor.

Authors:  J Borovicka; W Schwizer; G Guttmann; D Hartmann; M Kosinski; C Wastiel; A Bischof-Delaloye; M Fried
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

2.  A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium.

Authors:  N H Zangenberg; A Müllertz; H G Kristensen; L Hovgaard
Journal:  Eur J Pharm Sci       Date:  2001-09       Impact factor: 4.384

3.  THE INTRALUMINAL PHASE OF FAT DIGESTION IN MAN: THE LIPID CONTENT OF THE MICELLAR AND OIL PHASES OF INTESTINAL CONTENT OBTAINED DURING FAT DIGESTION AND ABSORPTION.

Authors:  A F HOFMANN; B BORGSTROEM
Journal:  J Clin Invest       Date:  1964-02       Impact factor: 14.808

4.  Surface behaviour of bile salts and tetrahydrolipstatin at air/water and oil/water interfaces.

Authors:  A Tiss; S Ransac; H Lengsfeld; P Hadvàry; A Cagna; R Verger
Journal:  Chem Phys Lipids       Date:  2001-05       Impact factor: 3.329

Review 5.  When poor solubility becomes an issue: from early stage to proof of concept.

Authors:  S Stegemann; F Leveiller; D Franchi; H de Jong; H Lindén
Journal:  Eur J Pharm Sci       Date:  2007-05-21       Impact factor: 4.384

6.  Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Authors:  René Holm; Christopher J H Porter; Anette Müllertz; Henning G Kristensen; William N Charman
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

7.  In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.

Authors:  Nicky Thomas; Katharina Richter; Thomas B Pedersen; René Holm; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2014-04-02       Impact factor: 4.009

8.  A dynamic in vitro lipolysis model. II: Evaluation of the model.

Authors:  N H Zangenberg; A Müllertz; H G Kristensen; L Hovgaard
Journal:  Eur J Pharm Sci       Date:  2001-10       Impact factor: 4.384

9.  Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats.

Authors:  Arik Dahan; Amnon Hoffman
Journal:  Pharm Res       Date:  2006-08-11       Impact factor: 4.200

10.  Transfer of orlistat through oil-water interfaces.

Authors:  Ali Tiss; Hans Lengsfeld; Paul Hadváry; Alain Cagna; Robert Verger
Journal:  Chem Phys Lipids       Date:  2002-10       Impact factor: 3.329

View more
  3 in total

1.  Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations.

Authors:  Scheyla D V S Siqueira; Anette Müllertz; Kirsten Gräeser; Georgia Kasten; Huiling Mu; Thomas Rades
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

2.  Analysis of 3D Prints by X-ray Computed Microtomography and Terahertz Pulsed Imaging.

Authors:  Daniel Markl; J Axel Zeitler; Cecilie Rasch; Maria Høtoft Michaelsen; Anette Müllertz; Jukka Rantanen; Thomas Rades; Johan Bøtker
Journal:  Pharm Res       Date:  2016-12-21       Impact factor: 4.200

3.  Impact of Ferroquine on the Solubilization of Artefenomel (OZ439) during in Vitro Lipolysis in Milk and Implications for Oral Combination Therapy for Malaria.

Authors:  Malinda Salim; Jamal Khan; Gisela Ramirez; Mubtasim Murshed; Andrew J Clulow; Adrian Hawley; Hanu Ramachandruni; Stephane Beilles; Ben J Boyd
Journal:  Mol Pharm       Date:  2019-03-04       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.